
Leadership burnout is the silent threat — here's what to do about it
In the world of business, leaders are often celebrated for their resilience, decisiveness, and ability to push through pressure. But behind the polished presentations and confident boardroom personas, many executives are quietly burning out.
Leadership burnout is a silent threat. And it doesn't just take a toll on the individual — it impacts the entire organization.
The hidden cost of executive exhaustion
When leaders are stretched too thin, everyone feels it. Burnout's emotional ripple effect trickles down to teams, the culture, and your customers. Decision-making suffers, innovation stalls, and morale dips. In today's unpredictable landscape, businesses can't afford to have their leaders operating on fumes.
Leadership fatigue at the top is more common than many realize. In fact, the Harvard Business Review reports that nearly 60% of leaders feel used up at the end of every workday. That number rises for women and Black, Indigenous and People of Color (BIPOC) leaders, many of whom navigate additional layers of invisible labor.
This is no longer just a wellness concern — it's a team and leadership issue.
Why burnout is a leadership development issue
Rather than viewing burnout and feeling overwhelmed as a personal failing, we must reframe them as a call to evolve leadership practices and how teams function.
At Henley Leadership Group, we work with leaders to shift the conversation from 'How can I power through this?' to 'What needs to change for me to lead sustainably?' Fatigue and exhaustion are often a sign that something deeper is misaligned — whether it's a lack of purpose, unclear expectations, or outdated operating rhythms.
This is where true leadership development begins — not with tactics, but with self-awareness.
Reclaiming your leadership focus
Through Henley's executive coaching and team development programs, we help leaders reconnect with who they are and how they want to lead. One key tool we use is our Power of Collaboration™ model — a framework designed to strengthen leadership from the inside out while building more effective, resilient teams.
The model focuses on five foundational elements:
Create a compelling why: Align your team around a meaningful purpose (outside of company vision and mission) that energizes and inspires effort.
Build trust: Develop healthy conflict skills, raise accountability, and match the right people to the right work.
Be inclusive: Foster a culture where a variety of voices are welcomed and respected, and contribute to the whole.
Voice what's good: To build momentum and morale, shift the team's focus from what's broken to what's working.
Have productive breakdowns: Learn from failure, recover quickly, and adapt to pursue your shared purpose.
This collaborative foundation doesn't just reduce leadership exhaustion, it revitalizes teams and leaders and helps organizations meet complexity with clarity, cohesion, and connection.
The cost of ignoring the signs
When burnout is left unaddressed, it often leads to turnover at the top, disengaged teams, and missed opportunities for innovation. But when leaders invest in their own growth, when they create space to reset, reconnect, and reimagine, they don't just bounce back. They come back clearer.
When a CEO or executive team models this kind of intentional leadership, it sends a powerful message: well-being and business performance are not at odds — they're intertwined.
It's time to normalize the reset
There's no shame in feeling burned out. There is, however, great wisdom in responding to that signal with action. Leadership today isn't about pushing harder — it's about leading smarter.
The most effective leaders we work with have embraced the idea that burnout is a message, not a verdict. It's a message that something needs to shift. And often, that shift unlocks the next level of team and personal leadership potential.
So if you're feeling stretched thin — or see the signs in someone on your team — consider it your invitation to reimagine what leadership can look like.
If you or your executive team is ready to lead from a place of clarity and purpose, Henley Leadership Group can help. Learn more about our executive coaching and team development programs.
Henley Leadership Group is a Seattle-based leadership development firm specializing in executive coaching, leadership and team development, and custom team offsites. We help leaders grow from the inside out. Learn more at www.henleyleadership.com.
Carol Zizzo is the CEO of Henley Leadership Group and a seasoned executive coach with over two decades of experience helping leaders build trust, clarity, and alignment. She is passionate about helping leaders access their full potential and lead with heart, purpose, and impact.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ('Jupiter' or the 'Company'), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. 'The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'By building on the same proprietary technology platform that underpins our prescription drug development, we're delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.' A New Standard in Evidence-Based Supplementation Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL™, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL™ is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease. Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. 'We cracked the code on resveratrol's widely published issue with bioavailability, and now we're unlocking its potential beyond the clinic,' added Rosén. 'Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.' Strategic Synergy with Core Pipeline The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030. The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model. 'Nugevia represents more than a product launch—it's a strategic engine for growth,' said Rosén. 'By leveraging our core science in a consumer format, we're creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It's smart capital allocation with real scientific impact.' A digital press kit, including high-resolution product imagery and key brand information, is available at . About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson's Disease. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@
Yahoo
38 minutes ago
- Yahoo
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. "We are thrilled to soon launch BYQLOVI, a truly clinically differentiated topical corticosteroid, into a U.S. market that now exceeds 7 million annual ophthalmic surgeries," said Mark L. Baum, Chief Executive Officer of Harrow. "With compelling efficacy, extraordinary safety, and patient‑friendly dosing, BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment." "Harrow's commitment to innovation, patient access, and physician engagement closely aligns with our mission to promote unique clinical advancements that improve patient outcomes," said Erick Co, President and CEO of Formosa Pharmaceuticals. "We are confident that Harrow's leadership in the U.S. eyecare space will ensure BYQLOVI's successful adoption among surgeons and eyecare professionals – and ultimately, better post-surgical experiences for U.S. patients." BYQLOVI, a high-potency ophthalmic corticosteroid formulated using Formosa's proprietary APNT® nanoparticle formulation technology, delivers a highly uniform suspension that minimizes particle setting and provides consistent dosing. Its pharmacologic performance and clinical outcomes position it as a best‑in‑class option for post-operative inflammation and pain. Key highlights of BYQLOVI include: Best-in-Class Pain Relief with 77% and 85%, respectively, of patients in supportive pivotal clinical studies reporting no pain at Day 4 post-surgery; 82% and 87%, respectively, reporting no pain at Day 8 post-surgery. Best-in-Class Inflammation Clearance with 33% and 30%, respectively, of patients in supportive pivotal clinical studies with zero cell counts in the anterior chamber at Day 8 post-surgery. Safety Benefits with only 1.4% of patients experiencing elevated intraocular pressure (IOP), a substantially lower rate compared to other ophthalmic steroids. Best-in-Class Post-Surgical Dosing at 1 drop BID dosing for 14 days on label; without the need for a loading dose and a maintenance phase. About BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05% BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. WARNINGS AND PRECAUTIONS Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, IOP should be monitored. Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Delayed Healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Corneal and Scleral Melting: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate. ADVERSE REACTIONS Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure. USE IN SPECIAL POPULATIONS Pregnancy. There are no adequate and well-controlled studies of BYQLOVI administration in pregnant women to inform a drug-associated risk. For additional information about BYQLOVI™, please see the Full Prescribing Information. About Formosa Pharmaceuticals Formosa Pharmaceuticals, Inc. ( is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which BYQLOVI was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. View original content to download multimedia: SOURCE Formosa Pharmaceuticals Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Axios
42 minutes ago
- Axios
Why unemployment for Black women is rising
The jobless rate for Black women has been creeping higher all year. Why it matters: This could be a sign of weakness in the overall job market, economists say, though others point to the Trump administration's purge of the federal workforce and its push to eliminate DEI efforts. By the numbers: The demographic-level data on unemployment from the Labor Department can be volatile month-to-month, so Axios looked at the three-month trailing average, based on the jobs numbers released Friday. By this measure, Black women's unemployment rose to 5.8% in May, up from 5.3% a year ago, surpassing the jobless rate for Black men, which declined to 5.6%. For white women, the jobless rate has stayed relatively flat. While it rose for white men, their unemployment rate is still below the overall number. The intrigue: The share of Black women working in the federal government shrank nearly 33% over the past year, per data cited by Bloomberg last month. Between the lines: Women comprise a slight minority of the federal workforce but represent the majority of employees among the agencies targeted by the White House, including USAID, the Consumer Financial Protection Bureau and the Department of Education, where Black women make up 28% of workers. Women also make up a greater share of probationary workers, the National Women's Law Center notes. Black women are overrepresented in the federal employment compared with the private sector, accounting for nearly 12% of the federal workforce in 2020, compared with about 7% in the civilian labor force, according to a federal report. Zoom out: It's "largely an untold story," according to a ProPublica report last week on how firings have disproportionately impacted Black women. Federal contract work has also fallen, though those numbers are harder to come by. "The layoffs at the federal level where Black people are more represented, the impacts of the tariffs, particularly on small businesses that hire Black women, and the overall use of DEI as a slur, which may be contributing to a lack of hiring of Black women, all of these factors are probably at play," Andre Perry, senior fellow at the Brookings Institution told Bloomberg. Reality check: The federal job loss doesn't fully explain the decline in overall employment for Black women. Federal employment has fallen by 69,000 this year, per the Bureau of Labor Statistics, but the number is expected to move higher, since those on paid leave or receiving severance are counted as employed. From January to March, Black women's employment fell by a whopping 306,000. It has recovered a bit since then and now is down by 233,000 for the year to date. "It's a really large drop and it can't just be the federal layoffs," according to Jessica Fulton, senior fellow at the Joint Center for Political and Economic Studies. What to watch: Black unemployment in the U.S. always trends higher than the overall number. Historically it has been double the rate of white workers, but that gap narrowed a bit in the post-pandemic job market. A higher Black unemployment rate can be an early recession warning sign, Fulton says.